Drug Type Unknown |
Synonyms INCA-036978 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Myeloproliferative Disorders | Phase 1 | United States | 11 May 2026 | |
| Myeloproliferative Disorders | Phase 1 | Japan | 11 May 2026 | |
| Myeloproliferative Disorders | Phase 1 | Australia | 11 May 2026 | |
| Myeloproliferative Disorders | Phase 1 | Belgium | 11 May 2026 | |
| Myeloproliferative Disorders | Phase 1 | Canada | 11 May 2026 | |
| Myeloproliferative Disorders | Phase 1 | France | 11 May 2026 | |
| Myeloproliferative Disorders | Phase 1 | Germany | 11 May 2026 | |
| Myeloproliferative Disorders | Phase 1 | Italy | 11 May 2026 | |
| Myeloproliferative Disorders | Phase 1 | Spain | 11 May 2026 | |
| Myeloproliferative Disorders | Phase 1 | United Kingdom | 11 May 2026 |





